These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36755068)

  • 1. MNT suppresses T cell apoptosis via BIM and is critical for T lymphomagenesis.
    Nguyen HV; Vandenberg CJ; Robati MR; Ng AP; Cory S
    Cell Death Differ; 2023 Apr; 30(4):1018-1032. PubMed ID: 36755068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis.
    Nguyen HV; Vandenberg CJ; Ng AP; Robati MR; Anstee NS; Rimes J; Hawkins ED; Cory S
    Blood; 2020 Mar; 135(13):1019-1031. PubMed ID: 31978211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance.
    Campbell KJ; Bath ML; Turner ML; Vandenberg CJ; Bouillet P; Metcalf D; Scott CL; Cory S
    Blood; 2010 Oct; 116(17):3197-207. PubMed ID: 20631380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mnt modulates Myc-driven lymphomagenesis.
    Campbell KJ; Vandenberg CJ; Anstee NS; Hurlin PJ; Cory S
    Cell Death Differ; 2017 Dec; 24(12):2117-2126. PubMed ID: 28800127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of a Single Mcl-1 Allele Inhibits MYC-Driven Lymphomagenesis by Sensitizing Pro-B Cells to Apoptosis.
    Grabow S; Delbridge AR; Aubrey BJ; Vandenberg CJ; Strasser A
    Cell Rep; 2016 Mar; 14(10):2337-47. PubMed ID: 26947081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myc suppression of Nfkb2 accelerates lymphomagenesis.
    Keller U; Huber J; Nilsson JA; Fallahi M; Hall MA; Peschel C; Cleveland JL
    BMC Cancer; 2010 Jul; 10():348. PubMed ID: 20598117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory disease and lymphomagenesis caused by deletion of the Myc antagonist Mnt in T cells.
    Dezfouli S; Bakke A; Huang J; Wynshaw-Boris A; Hurlin PJ
    Mol Cell Biol; 2006 Mar; 26(6):2080-92. PubMed ID: 16507988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
    Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
    Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The activities of MYC, MNT and the MAX-interactome in lymphocyte proliferation and oncogenesis.
    Link JM; Hurlin PJ
    Biochim Biophys Acta; 2015 May; 1849(5):554-62. PubMed ID: 24731854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice.
    Kelly PN; Grabow S; Delbridge AR; Strasser A; Adams JM
    Blood; 2011 Dec; 118(24):6380-6. PubMed ID: 21998213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell lymphomas mask slower developing B-lymphoid and myeloid tumours in transgenic mice with broad haemopoietic expression of MYC.
    Smith DP; Bath ML; Harris AW; Cory S
    Oncogene; 2005 May; 24(22):3544-53. PubMed ID: 15688022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IBTK Haploinsufficiency Affects the Tumor Microenvironment of Myc-Driven Lymphoma in E-myc Mice.
    Vecchio E; Fiume G; Mignogna C; Iaccino E; Mimmi S; Maisano D; Trapasso F; Quinto I
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019112
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Mathsyaraja H; Freie B; Cheng PF; Babaeva E; Catchpole JT; Janssens D; Henikoff S; Eisenman RN
    Genes Dev; 2019 Sep; 33(17-18):1252-1264. PubMed ID: 31395740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IgH enhancer deregulated expression of L-myc: abnormal T lymphocyte development and T cell lymphomagenesis.
    Möröy T; Fisher P; Guidos C; Ma A; Zimmerman K; Tesfaye A; DePinho R; Weissman I; Alt FW
    EMBO J; 1990 Nov; 9(11):3659-66. PubMed ID: 2120050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deletion of the transcriptional regulator TFAP4 accelerates c-MYC-driven lymphomagenesis.
    Potts MA; Mizutani S; Garnham AL; Li Wai Suen CSN; Kueh AJ; Tai L; Pal M; Strasser A; Herold MJ
    Cell Death Differ; 2023 Jun; 30(6):1447-1456. PubMed ID: 36894688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A critical role for Mnt in Myc-driven T-cell proliferation and oncogenesis.
    Link JM; Ota S; Zhou ZQ; Daniel CJ; Sears RC; Hurlin PJ
    Proc Natl Acad Sci U S A; 2012 Nov; 109(48):19685-90. PubMed ID: 23150551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uncovering MYC's full oncogenic potential in the hematopoietic system.
    Janz S
    Oncogene; 2005 May; 24(22):3541-3. PubMed ID: 15782131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical B-lymphoid cell intrinsic role of endogenous MCL-1 in c-MYC-induced lymphomagenesis.
    Grabow S; Kelly GL; Delbridge AR; Kelly PN; Bouillet P; Adams JM; Strasser A
    Cell Death Dis; 2016 Mar; 7(3):e2132. PubMed ID: 26962682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mnt-deficient mammary glands exhibit impaired involution and tumors with characteristics of myc overexpression.
    Toyo-oka K; Bowen TJ; Hirotsune S; Li Z; Jain S; Ota S; Escoubet-Lozach L; Garcia-Bassets I; Lozach J; Rosenfeld MG; Glass CK; Eisenman R; Ren B; Hurlin P; Wynshaw-Boris A
    Cancer Res; 2006 Jun; 66(11):5565-73. PubMed ID: 16740691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of B-cell lymphomagenesis by the BH3-only proteins Bmf and Bad.
    Frenzel A; Labi V; Chmelewskij W; Ploner C; Geley S; Fiegl H; Tzankov A; Villunger A
    Blood; 2010 Feb; 115(5):995-1005. PubMed ID: 19965635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.